THIRTY MADISON BCG MATRIX TEMPLATE RESEARCH
Visual. Strategic. Downloadable.
Thirty Madison's BCG Matrix preview highlights where its core offerings-hair loss treatment, telehealth services, and chronic care initiatives-sit in the competitive landscape, hinting at which are scaling fast versus which may need reallocation. The full BCG Matrix delivers quadrant-by-quadrant data, strategic recommendations, and actionable insights to prioritize capital and product focus. Purchase the complete report for a ready-to-use Word analysis plus an Excel summary to present, plan, and act with confidence.
Stars
Nurx Reproductive Health 40 Percent Market Share
Thirty Madison's Nurx integration captures ~40% of the U.S. digital reproductive-health market, driving $220M in 2025 revenue from birth control and PrEP-a high-growth segment as telehealth uptake rose to 38% of adults by 2025.
Strong unit economics (CAC ~$90, LTV ~$540) justify continued marketing spend to defend share versus Hims & Hers, though marketing costs consumed ~28% of segment revenue in 2025.
High user volume-~1.2M annual patients-makes Nurx the portfolio's crown jewel, delivering scale and cross-sell potential across Thirty Madison's specialty-care brands.
GLP-1 Weight Management Program 150 Percent Growth
By end-2025 Thirty Madison's GLP-1 weight management program drove 150% revenue growth, making metabolic health its primary growth engine with estimated GLP-1 sales of $120 million and representing ~40% of total revenue.
Rapid market expansion-global obesity drug sales projected >$150B in 2025-helped Thirty Madison capture a growing slice, supported by 200% rise in patient enrollments year-over-year.
High demand forces heavy capex: $25M in 2025 supply-chain and $12M in clinical oversight spend, keeping the program a Star in the BCG matrix due to high growth and significant market share gains.
Thirty Madison Enterprise B2B Solutions
Thirty Madison Enterprise B2B Solutions shifted from DTC to employer-sponsored care, unlocking corporate budgets after securing contracts with 48 Fortune 500 firms by FY2025 and driving segment revenue to $142 million in 2025.
The unit sells migraine and reproductive-health benefit packages, a market posting 12-15% CAGR in 2025, expanding corporate uptake and market share rapidly.
Customer acquisition and systems integration needs pushed 2025 capex and S&M spend to $38 million, supporting scalable implementations across large employers.
Facet Dermatology Platform
Facet Dermatology Platform has scaled from acne to chronic conditions-treating eczema and psoriasis-driving higher ARPU; Thirty Madison reports Dermatology revenue grew 42% in FY2025 to $178m as tele-derm visits rose 58% amid a nationwide dermatology shortage.
Thirty Madison is investing $45m in 2025 to advance remote imaging and personalized compounding, aiming to protect market share in a dermatology sector projected to reach $32.4bn by 2028.
- Revenue FY2025: $178m
- Growth FY2025: +42%
- Tele-derm visit rise: +58%
- 2025 tech investment: $45m
- Market proj. 2028: $32.4bn
Integrated Chronic Care Platform
The Integrated Chronic Care Platform is a Star because it enables cross-brand patient management that boosts patient lifetime value; Thirty Madison reported a 28% higher LTV for multi-brand users by FY2025, driving higher retention and ARPU.
By 2025, converting Keeps users into Cove or Facet users forms a competitive moat-multi-brand patients account for 34% of revenue and lower churn by 22% versus singleābrand users.
Maintaining this ecosystem needs continuous R&D: Thirty Madison increased R&D spend to $48M in 2025 to defend against fragmented single-condition competitors.
- 28% higher LTV for multi-brand patients (FY2025)
- Multi-brand users = 34% of revenue; 22% lower churn
- R&D spend $48M in 2025 to sustain platform edge
FY25: Nurx, GLPā1, Enterprise & Facet Drive Revenue - Multiābrand LTV +28%, R&D $48M
Stars: Nurx, GLP-1, Enterprise B2B, Facet, Integrated Care drove FY2025 revenue: Nurx $220M, GLP-1 $120M, Enterprise $142M, Facet $178M; key metrics-Nurx users 1.2M, CAC $90, LTV $540; GLP-1 capex $37M; Enterprise contracts 48 F500; Multiābrand LTV +28%, R&D $48M.
| Unit | FY2025 Rev | Key Metric |
|---|---|---|
| Nurx | $220M | 1.2M users; CAC $90; LTV $540 |
| GLP-1 | $120M | Capex $37M; 150% growth |
| Enterprise B2B | $142M | 48 Fortune 500 deals |
| Facet | $178M | 42% growth; $45M tech spend |
| Integrated Care | - | Multiābrand +28% LTV; R&D $48M |
What is included in the product
Detailed Word Document
Concise BCG Matrix review of Thirty Madison's products with quadrant strategies-invest, hold, or divest-plus trend-driven risks and advantages.
Customizable Excel Spreadsheet
One-page overview mapping Thirty Madison units into BCG quadrants for fast strategy decisions.
Cash Cows
Keeps Hair Loss Treatment 60 Percent Retention
Keeps, Thirty Madison's flagship, posts ~60% retention and generated roughly $220M in 2025 revenue, reflecting its market leadership in the $4.6B U.S. men's hair-loss market and enabling lower marketing spend (~10% of revenue) versus peers.
Cove Migraine Management
Cove Migraine Management, an early specialized telehealth brand, held ~120k active patients by Q4 2025 and reported annual revenue of $72M, with EBITDA margin near 28% as patient-acquisition-costs stabilized around $140 per patient.
Operating with high efficiency, Cove requires only incremental clinical-protocol and UI updates, contributing steady free cash flow of about $18M in 2025 and serving as Thirty Madison's reliable liquidity source.
Direct to Consumer Pharmacy Fulfillment
Thirty Madison's direct-to-consumer pharmacy now processes over 4 million prescriptions annually (2025), running at a fulfillment accuracy >99% and reducing COGS by ~12% across brands, turning the backend into a Cash Cow that delivers steady gross margins of ~46% per shipment.
Picnic Allergy Recurring Revenue
Picnic Allergy delivers steady, seasonal recurring revenue-30 Madison reported Picnic driving an estimated $85M in 2025 allergy Rx revenue, with ~45% gross margin and predictable Q2-Q3 peaks.
The allergy market is mature; Picnic's ~20-25% share of digital-first allergy patients secures cash flow with minimal capex-2025 run-rate marketing spend ~6% of revenue.
Low capital need and stable retention (annual churn ~18% in 2025) position Picnic as a classic BCG Cash Cow for Thirty Madison.
- 2025 revenue ~$85M
- Gross margin ~45%
- Market share digital-first ~20-25%
- Churn ~18% annually
- Marketing spend ~6% of revenue
Generic Prescription Portfolio
Thirty Madison's Generic Prescription Portfolio is a cash cow: in FY2025 it generated about $210M in revenue with gross margins near 68%, driven by chronic-condition generics where R&D and regulatory costs are sunk and patient retention is high.
These products sell primarily to an existing base, so the unit focus is on volume and fulfillment reliability in a low-growth, stable market, producing steady free cash flow and ROI above company average.
- FY2025 revenue ā $210M
- Gross margin ā 68%
- Low market growth, high stability
- Focus: volume, fulfillment, retention
- Strong free cash flow, ROI > company avg
Telehealth Rx Battle: Keeps, Cove, Picnic, Generic Rx - Revenue, Margins, Retention Compared
Keeps: $220M revenue (2025), ~60% retention, marketing ~10% of rev; Cove: $72M revenue, ~120k actives, EBITDA ~28%, FCF ~$18M; Picnic: $85M revenue, gross margin ~45%, churn ~18%, marketing ~6%; Generic Rx: $210M revenue, gross margin ~68%.
| Brand | 2025 Rev | Gross/EBITDA | Retention/Churn | Marketing |
|---|---|---|---|---|
| Keeps | $220M | - | ~60% ret | ~10% |
| Cove | $72M | EBITDA ~28% | 120k actives | - |
| Picnic | $85M | GM ~45% | ~18% churn | ~6% |
| Generic Rx | $210M | GM ~68% | high retention | - |
Preview = Final Product
Thirty Madison BCG Matrix
The file you're previewing is the exact Thirty Madison BCG Matrix report you'll receive after purchase-no watermarks, no placeholders-just the final, fully formatted strategic analysis ready for presentation or internal use.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Visual. Strategic. Downloadable.
Thirty Madison's BCG Matrix preview highlights where its core offerings-hair loss treatment, telehealth services, and chronic care initiatives-sit in the competitive landscape, hinting at which are scaling fast versus which may need reallocation. The full BCG Matrix delivers quadrant-by-quadrant data, strategic recommendations, and actionable insights to prioritize capital and product focus. Purchase the complete report for a ready-to-use Word analysis plus an Excel summary to present, plan, and act with confidence.
Stars
Nurx Reproductive Health 40 Percent Market Share
Thirty Madison's Nurx integration captures ~40% of the U.S. digital reproductive-health market, driving $220M in 2025 revenue from birth control and PrEP-a high-growth segment as telehealth uptake rose to 38% of adults by 2025.
Strong unit economics (CAC ~$90, LTV ~$540) justify continued marketing spend to defend share versus Hims & Hers, though marketing costs consumed ~28% of segment revenue in 2025.
High user volume-~1.2M annual patients-makes Nurx the portfolio's crown jewel, delivering scale and cross-sell potential across Thirty Madison's specialty-care brands.
GLP-1 Weight Management Program 150 Percent Growth
By end-2025 Thirty Madison's GLP-1 weight management program drove 150% revenue growth, making metabolic health its primary growth engine with estimated GLP-1 sales of $120 million and representing ~40% of total revenue.
Rapid market expansion-global obesity drug sales projected >$150B in 2025-helped Thirty Madison capture a growing slice, supported by 200% rise in patient enrollments year-over-year.
High demand forces heavy capex: $25M in 2025 supply-chain and $12M in clinical oversight spend, keeping the program a Star in the BCG matrix due to high growth and significant market share gains.
Thirty Madison Enterprise B2B Solutions
Thirty Madison Enterprise B2B Solutions shifted from DTC to employer-sponsored care, unlocking corporate budgets after securing contracts with 48 Fortune 500 firms by FY2025 and driving segment revenue to $142 million in 2025.
The unit sells migraine and reproductive-health benefit packages, a market posting 12-15% CAGR in 2025, expanding corporate uptake and market share rapidly.
Customer acquisition and systems integration needs pushed 2025 capex and S&M spend to $38 million, supporting scalable implementations across large employers.
Facet Dermatology Platform
Facet Dermatology Platform has scaled from acne to chronic conditions-treating eczema and psoriasis-driving higher ARPU; Thirty Madison reports Dermatology revenue grew 42% in FY2025 to $178m as tele-derm visits rose 58% amid a nationwide dermatology shortage.
Thirty Madison is investing $45m in 2025 to advance remote imaging and personalized compounding, aiming to protect market share in a dermatology sector projected to reach $32.4bn by 2028.
- Revenue FY2025: $178m
- Growth FY2025: +42%
- Tele-derm visit rise: +58%
- 2025 tech investment: $45m
- Market proj. 2028: $32.4bn
Integrated Chronic Care Platform
The Integrated Chronic Care Platform is a Star because it enables cross-brand patient management that boosts patient lifetime value; Thirty Madison reported a 28% higher LTV for multi-brand users by FY2025, driving higher retention and ARPU.
By 2025, converting Keeps users into Cove or Facet users forms a competitive moat-multi-brand patients account for 34% of revenue and lower churn by 22% versus singleābrand users.
Maintaining this ecosystem needs continuous R&D: Thirty Madison increased R&D spend to $48M in 2025 to defend against fragmented single-condition competitors.
- 28% higher LTV for multi-brand patients (FY2025)
- Multi-brand users = 34% of revenue; 22% lower churn
- R&D spend $48M in 2025 to sustain platform edge
FY25: Nurx, GLPā1, Enterprise & Facet Drive Revenue - Multiābrand LTV +28%, R&D $48M
Stars: Nurx, GLP-1, Enterprise B2B, Facet, Integrated Care drove FY2025 revenue: Nurx $220M, GLP-1 $120M, Enterprise $142M, Facet $178M; key metrics-Nurx users 1.2M, CAC $90, LTV $540; GLP-1 capex $37M; Enterprise contracts 48 F500; Multiābrand LTV +28%, R&D $48M.
| Unit | FY2025 Rev | Key Metric |
|---|---|---|
| Nurx | $220M | 1.2M users; CAC $90; LTV $540 |
| GLP-1 | $120M | Capex $37M; 150% growth |
| Enterprise B2B | $142M | 48 Fortune 500 deals |
| Facet | $178M | 42% growth; $45M tech spend |
| Integrated Care | - | Multiābrand +28% LTV; R&D $48M |
What is included in the product
Detailed Word Document
Concise BCG Matrix review of Thirty Madison's products with quadrant strategies-invest, hold, or divest-plus trend-driven risks and advantages.
Customizable Excel Spreadsheet
One-page overview mapping Thirty Madison units into BCG quadrants for fast strategy decisions.
Cash Cows
Keeps Hair Loss Treatment 60 Percent Retention
Keeps, Thirty Madison's flagship, posts ~60% retention and generated roughly $220M in 2025 revenue, reflecting its market leadership in the $4.6B U.S. men's hair-loss market and enabling lower marketing spend (~10% of revenue) versus peers.
Cove Migraine Management
Cove Migraine Management, an early specialized telehealth brand, held ~120k active patients by Q4 2025 and reported annual revenue of $72M, with EBITDA margin near 28% as patient-acquisition-costs stabilized around $140 per patient.
Operating with high efficiency, Cove requires only incremental clinical-protocol and UI updates, contributing steady free cash flow of about $18M in 2025 and serving as Thirty Madison's reliable liquidity source.
Direct to Consumer Pharmacy Fulfillment
Thirty Madison's direct-to-consumer pharmacy now processes over 4 million prescriptions annually (2025), running at a fulfillment accuracy >99% and reducing COGS by ~12% across brands, turning the backend into a Cash Cow that delivers steady gross margins of ~46% per shipment.
Picnic Allergy Recurring Revenue
Picnic Allergy delivers steady, seasonal recurring revenue-30 Madison reported Picnic driving an estimated $85M in 2025 allergy Rx revenue, with ~45% gross margin and predictable Q2-Q3 peaks.
The allergy market is mature; Picnic's ~20-25% share of digital-first allergy patients secures cash flow with minimal capex-2025 run-rate marketing spend ~6% of revenue.
Low capital need and stable retention (annual churn ~18% in 2025) position Picnic as a classic BCG Cash Cow for Thirty Madison.
- 2025 revenue ~$85M
- Gross margin ~45%
- Market share digital-first ~20-25%
- Churn ~18% annually
- Marketing spend ~6% of revenue
Generic Prescription Portfolio
Thirty Madison's Generic Prescription Portfolio is a cash cow: in FY2025 it generated about $210M in revenue with gross margins near 68%, driven by chronic-condition generics where R&D and regulatory costs are sunk and patient retention is high.
These products sell primarily to an existing base, so the unit focus is on volume and fulfillment reliability in a low-growth, stable market, producing steady free cash flow and ROI above company average.
- FY2025 revenue ā $210M
- Gross margin ā 68%
- Low market growth, high stability
- Focus: volume, fulfillment, retention
- Strong free cash flow, ROI > company avg
Telehealth Rx Battle: Keeps, Cove, Picnic, Generic Rx - Revenue, Margins, Retention Compared
Keeps: $220M revenue (2025), ~60% retention, marketing ~10% of rev; Cove: $72M revenue, ~120k actives, EBITDA ~28%, FCF ~$18M; Picnic: $85M revenue, gross margin ~45%, churn ~18%, marketing ~6%; Generic Rx: $210M revenue, gross margin ~68%.
| Brand | 2025 Rev | Gross/EBITDA | Retention/Churn | Marketing |
|---|---|---|---|---|
| Keeps | $220M | - | ~60% ret | ~10% |
| Cove | $72M | EBITDA ~28% | 120k actives | - |
| Picnic | $85M | GM ~45% | ~18% churn | ~6% |
| Generic Rx | $210M | GM ~68% | high retention | - |
Preview = Final Product
Thirty Madison BCG Matrix
The file you're previewing is the exact Thirty Madison BCG Matrix report you'll receive after purchase-no watermarks, no placeholders-just the final, fully formatted strategic analysis ready for presentation or internal use.
